Helene Salmon, PhD
About Me
Dr Hélène Salmon did her PhD in Alain Trautmann and Emmanuel Donnadieu’s team in Paris where she studied T
cell migration in human lung tumors through live imaging, and showed the key role played by the extracellular matrix in regulating T cell motility and distribution at the tumor site.
Dr Salmon then joined the Merad laboratory and learned about myeloid cell biology to develop immunotherapeutic strategies modulating this cell compartment in solid tumors to enhance clinical response to existing therapies. She showed that the paucity of activated CD103+ dendritic cells (DCs) in tumors limits checkpoint blockade efficacy. Expansion and activation of CD103+ DC progenitors at the tumor site promote T cell activation and entry into the tumor, improving tumor response to PD-L1 inhibition (Immunity 2016).
Taking advantage of her expertise in cell dynamics and the tumor microenvironment, Dr Hélène Salmon has started a research program focused on the understanding of stroma contribution to tumor immunity.
Dr Salmon then joined the Merad laboratory and learned about myeloid cell biology to develop immunotherapeutic strategies modulating this cell compartment in solid tumors to enhance clinical response to existing therapies. She showed that the paucity of activated CD103+ dendritic cells (DCs) in tumors limits checkpoint blockade efficacy. Expansion and activation of CD103+ DC progenitors at the tumor site promote T cell activation and entry into the tumor, improving tumor response to PD-L1 inhibition (Immunity 2016).
Taking advantage of her expertise in cell dynamics and the tumor microenvironment, Dr Hélène Salmon has started a research program focused on the understanding of stroma contribution to tumor immunity.
Language
Research Topics
Anti-Tumor Therapy, Dendritic Cells, Imaging, Immunology, T Cells, Trafficking, Translational Research
